US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CAR-T Concept

1,719.02

-6.5424-0.38%

Number of Gainers:- -

Number of Losers:2

Number of Flat:- -

PE:- -

High:1,742.20

Open:1,728.53

Low:1,717.08

Close:1,725.57

Volume:7.52M

Turnover:1.07B

Market Cap:443.02B

Float Cap:434.81B

Loading ...

Novartis Stock (NVS) Sinks on Another Setback, Muscle-Wasting Disorder Drug Disappoints

Pharmaceutical Giant's Shares Plunge Nearly 10% Following Triple Clinical Trial Setbacks

Novartis Might Need More Deals to Deliver Growth Ambitions

Why the Dow is Being Dragged Down by a Swiss Company's Bad News

Novartis's Latest Trial Setback Sinks Stock

Novartis Genetic Muscle Disorder Drug Fails Phase 3 Trial; Shares Drop Pre-Bell

MT Newswires Live

United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday

Benzinga Earnings

Novartis's Latest Trial Failure is Second Pipeline Setback in a Row

European Equities Remain Flat as Energy Gains Offset by Pharma Slump

Gilead Sciences (GILD) Receives a Buy from Bernstein

Novartis AG Falls Monday, Underperforms Market

Citi says Novartis news increases likelihood Crispr prioritizes next-gen CTX321

Citi sees limited immediate downside for Ionis after pelacarsen failure

BofA sees low single-digit percentage downside for Novartis on pelacarsen miss

Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial

Novartis India to Acquire 'Minipress' Trademarks from Pfizer

Second Clinical Trial Blow in a Week for Novartis as Heart Drug Disappoints, Dragging Down Amgen Shares

Novartis Heart-Trial Failure Could be Mitigated by Investor Caution

Novartis India - Deal Valued at 12.50 Bln Rupees

THOMSON REUTERS

Novartis Shares to Take Hit from Cholesterol Trial Failure

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/BK4578/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4578","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T Concept","latestPrice":1719.0243,"timestamp":1788983999999,"preClose":1725.5667,"halted":0,"volume":7520858,"delay":0,"changeRate":-0.003791,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-6.542358,"latestTime":"09-09 16:00:00 EDT","open":1728.5277,"high":1742.1954,"low":1717.0756,"amount":1073442851.560458,"amplitude":0.014557,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789047000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":8.314749,"peRate":46.628821,"turnoverRate":0.002435,"increases":0,"decrements":2,"flats":0,"marketCap":443016822784,"floatMarketCap":434813911040},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1742.1954,"amplitude":0.014557,"preClose":1725.5667,"low":1717.0756,"pbRate":"8.314749","latestPrice":1719.0243,"volume":7520858,"delay":0,"open":1728.5277,"prevYearClose":1612.5378,"prevWeekClose":1911.2454,"prevMonthClose":1830.2803,"prevQuarterClose":1768.1697,"fiveDayClose":1915.5463,"twentyDayClose":1798.1283,"sixtyDayClose":1737.5757,"secType":"PLATE","market":"US","turnoverRate":0.002435,"peRate":46.628821,"marketCap":443016822784,"floatMarketCap":434813911040,"timestamp":1788983999999,"nameCN":"CAR-T Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":0,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665261713","title":"Novartis Stock (NVS) Sinks on Another Setback, Muscle-Wasting Disorder Drug Disappoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2665261713","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665261713?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:03","pubTimestamp":1788858204,"startTime":"0","endTime":"0","summary":"Novartis ($NVS) stock plunged about 13% in Tuesday’s pre-market trading as the Swiss drugmaker’s experimental drug, del-desiran, for a muscle-wasti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/novartis-stock-nvs-sinks-on-another-setback-muscle-wasting-disorder-drug-disappoints?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/novartis-stock-nvs-sinks-on-another-setback-muscle-wasting-disorder-drug-disappoints?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B2B36J28.USD","MEDX","BK4578","IE0009355771.USD","BK4585","BK4532","BK4588","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","NVS","IE00B4R5TH58.HKD","LU0070302665.USD","IE00BJT1NW94.SGD","LU0320765489.SGD","LU0208291251.USD","BK4007","LU0211331839.USD","IE0002141913.USD","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125754221","title":"Pharmaceutical Giant's Shares Plunge Nearly 10% Following Triple Clinical Trial Setbacks","url":"https://stock-news.laohu8.com/highlight/detail?id=1125754221","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125754221?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:00","pubTimestamp":1788858037,"startTime":"0","endTime":"0","summary":"Swiss pharmaceutical heavyweight Novartis faced a turbulent trading session on Tuesday as its shares tumbled sharply following the disclosure that its experimental drug for muscular dystrophy,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4578","BMED","PPH","LU0211331839.USD","LU0208291251.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","NVS","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BK4532","IE0002141913.USD","IE00BJJMRZ35.SGD","IBBJ","PSYK","IBBQ","MDTX","BK4585","LU0320765489.SGD","BK4007","BK4588","MEDX","LU0070302665.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665323400","title":"Novartis Might Need More Deals to Deliver Growth Ambitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323400","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665323400?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:17","pubTimestamp":1788855420,"startTime":"0","endTime":"0","summary":"0817 GMT - Novartis's latest clinical-trial failure suggests the company might need more dealmaking to deliver on its ambition for steady growth beyond 2030, Jefferies analysts say in a research note. The Swiss drugmaker maintained its 2025-30 sales guidance as it said its neuromuscular drug del-desiran missed the main goal in a late-stage study. However, no comment was provided on the ambition to grow by mid-single percentage digits beyond 2030, the analysts say. Even with the recent success of a new multiple-sclerosis pill, it will be challenging to get confidence on the company's growth for the 2030s without del-desiran and del-brax, two drugs Novartis acquired from Avidity Biosciences, Jefferies says. As a result, dealmaking will likely remain part of Novartis's story, the analysts add. Shares fall 10%.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","PPH","IE00BFTCPJ56.SGD","BK4532","LU0208291251.USD","IE00B2B36J28.USD","LU0070302665.USD","NVS","BK4585","LU0320765489.SGD","IE00BJT1NW94.SGD","BK4578","BK4588","LU0211331839.USD","MEDX","BK4007","IE0002141913.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665532340","title":"Why the Dow is Being Dragged Down by a Swiss Company's Bad News","url":"https://stock-news.laohu8.com/highlight/detail?id=2665532340","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665532340?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:15","pubTimestamp":1788855300,"startTime":"0","endTime":"0","summary":"Bad news from Swiss pharmaceutical giant Novartis was weighing on the Dow on Tuesday.Investors returning from the Labor Day break could be forgiven for wondering if their eyes were deceiving them, but","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIB","BK4533","IE00B4R5TH58.HKD","BK4581","LU1983299246.USD","LU2112291526.USD","LU0889565916.HKD","LU2089984988.USD","BK4585","BK4588","LU1061106388.HKD","IE00B2B36J28.USD","IE0002141913.USD","LU0289739699.SGD","IBB","PJP","LU1057294990.SGD","BK4139","LU0058720904.USD","IE0009355771.USD","LU0109394709.USD","LU0320765992.SGD","MEDX","PPH","TBXU","IE00BFTCPJ56.SGD","BK4578","AMGN","LU1023059063.AUD","LU0320765489.SGD","BK4007","LU0868494617.USD","BBH","BK4599","LU0070302665.USD","IE00BJJMRZ35.SGD","PBE","LU0211331839.USD","BK4534","LU1571399168.USD","NAMS","IBBQ","BK4532","LU2242652126.USD","LU0122379950.USD","NVS","LU0208291251.USD","LU2468319806.SGD","BK4566","SG9999001440.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665323985","title":"Novartis's Latest Trial Setback Sinks Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323985","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665323985?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:01","pubTimestamp":1788854460,"startTime":"0","endTime":"0","summary":"Novartis shares plunged after the Swiss drugmaker said an experimental neuromuscular medicine missed the primary goal in a late-stage clinical trial, the latest blow to its efforts to find new growth ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","MEDX","LU0070302665.USD","PPH","BK4585","LU0211331839.USD","IE0002141913.USD","BK4588","IE0009355771.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0320765489.SGD","IE00B4R5TH58.HKD","BK4532","LU0208291251.USD","BK4578","BK4007","NVS","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665323534","title":"Novartis Genetic Muscle Disorder Drug Fails Phase 3 Trial; Shares Drop Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323534","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665323534?lang=en_us&edition=fundamental","pubTime":"2026-09-08 15:58","pubTimestamp":1788854332,"startTime":"0","endTime":"0","summary":"Novartis  said Tuesday its phase 3 Harbor study evaluating delpacibart etedesiran in patients with myotonic dystrophy type 1 failed to meet its primary endpoint of video hand opening time.The drug candidate for the genetic muscular disorder displayed signs of clinical activity for its secondary endpoints measuring muscle strength, daily living activities, and mobility during the trial, the company said.The company is analyzing the full dataset to decide future development plans while maintaining its five-year annual sales growth target of 5% to 6% through 2030, Novartis said.Shares of the company were down by more than 13% in Tuesday premarket activity.Price: 138.80, Change: -21.19, Percent Change: -13.24","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVS","MEDX","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4007","LU0208291251.USD","IE00B2B36J28.USD","BK4578","IE0009355771.USD","BK4532","IE00B4R5TH58.HKD","PPH","LU0320765489.SGD","BK4588","LU0070302665.USD","LU0211331839.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665402063","title":"United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2665402063","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665402063?lang=en_us&edition=fundamental","pubTime":"2026-09-08 15:11","pubTimestamp":1788851511,"startTime":"0","endTime":"0","summary":"Stocks in focus: UNFI and ABM earnings, Novartis trial miss, Co-Diagnostics CFO change, and Casey’s earnings expected.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/long-ideas/26/09/61650635/united-natural-foods-abm-industries-and-3-stocks-to-watch-heading-into-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","LU1267930730.SGD","BK4082","BK4120","FEBU","PMDE","VOTE","NVS","IE0002141913.USD","GXDW","IE00B4R5TH58.HKD","BK4578","FXG","BK4007","LU0708995401.HKD","IE00BFTCPJ56.SGD","MEDX","LU0211331839.USD","BK4532","LU0109391861.USD","BK4585","IE00B2B36J28.USD","DECU","PPH","CASY","IE0009354923.USD","LU0208291251.USD","BK4102","BK4588","RGLO","LU0320765489.SGD","LU0672654240.SGD","IE0009355771.USD","JOYT","LU1878469433.USD","CODX","UNFI","LU0070302665.USD","LU0320765059.SGD","BK4113","VGFPF","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","ABM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665034034","title":"Novartis's Latest Trial Failure is Second Pipeline Setback in a Row","url":"https://stock-news.laohu8.com/highlight/detail?id=2665034034","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665034034?lang=en_us&edition=fundamental","pubTime":"2026-09-08 14:46","pubTimestamp":1788849960,"startTime":"0","endTime":"0","summary":"0646 GMT - Novartis just suffered its second major pipeline setback in the past week after a drug candidate it acquired through its recent $12 billion Avidity Biosciences deal failed in a late-stage study, Vontobel's Stefan Schneider says in a research note. News that experimental drug del-desiran missed the goal in a trial for neuromuscular disease myotonic dystrophy type 1 comes after the Swiss pharmaceutical company last week reported disappointing results for cardiovascular medicine pelacarsen. Vontobel had forecast annual peak sales from del-desiran at $3 billion, with a 50% chance of reaching them, and now removes this forecast from its model. As a result, Vontobel cuts its target price on Novartis stock to 125 Swiss francs from 128 francs. Novartis shares closed at 125.46 francs on Monday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","LU0070302665.USD","LU0320765489.SGD","IE0009355771.USD","IE00BJJMRZ35.SGD","BK4588","BK4585","IE0002141913.USD","IE00B2B36J28.USD","BK4007","MEDX","PPH","BK4532","LU0211331839.USD","BK4578","IE00B4R5TH58.HKD","LU0208291251.USD","IE00BJT1NW94.SGD","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193693103","title":"European Equities Remain Flat as Energy Gains Offset by Pharma Slump","url":"https://stock-news.laohu8.com/highlight/detail?id=1193693103","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193693103?lang=en_us&edition=fundamental","pubTime":"2026-09-08 00:30","pubTimestamp":1788798644,"startTime":"0","endTime":"0","summary":"European markets closed Monday with little movement, as rising crude prices and a sharp decline in a major pharmaceutical firm counterbalanced each other. The benchmark Stoxx Europe 600 index...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENHI","TDI","FDEV","FIEE","IEV","AIVI","EPV","IE0002141913.USD","IDUB","XEUR","SPEU","BBIN","IE00BJT1NW94.SGD","XES","IFV","IEO","PPIE","QBIV","RFEU","IEUR","BRIE","PIEQ","YDEC","IEFA","GIEQ","JDVI","TACN","PQIN","IDJN","BK4504","BK4585","OIH","STXI","INOV","NIHI","IFEB","OILK","REFA","ISWN","OPPE","BK4588","IGGY","JHMD","QEFA","EPIN","BWET","YSEP","PTEU","EURL","FDT","PIZ","SSXU","USL","BK4581","HEFA","GSEU","IJAN","PPH","PZIV","XLEX","ESIM","CWI","EFO","MFSI","DTAN","RAYD","RDMX","JPIN","PGRI","UPV","NUDM","FSZ","INTF","XEML","IAPR","IDEQ","FFDI","VEA","PTIN","FEDM","AVNM","MFDX","GLBL","IDEC","UAE","XW","RODE","KOKU","DBEF","FTXN","IVAL","CGXU","AVIV","JIRE","TLTD","PXE","FEOE","FEZ","BK4167","ISEP","BK4582","DFIC","FEP","IFLR","IOCT","ITOL","IE00B4R5TH58.HKD","GXUS","CGIE","ICOW","URTH","OILU","DMXF","NVS","ICPY","AVDE","CGIC","DDWM","GUSH","BK4532","GLOF","EAFG","SCHF","GSID","IMOM","PXF","TOK","PXJ","BK4534","FLEE","VOOV","ILOW","EWN","FENI","BKCI","EFAX","IDMY","VNIE","BK4570","LU0208291251.USD","AVSD","IE00BFTCPJ56.SGD","OILT","TPOR","VGK","DEEF","IMTM","DUG","IE0009355771.USD","ISDX","BK4007","VIDI","QLVD","IE00B2B36J28.USD","JANI","FINT","IDME","DBO","BUFY","DFAX","LU0211331839.USD","DFAI","BKIE","SDOG","BBEU","IQLT","EFA","TPIF","BINV","ACWX","YMAR","IE00BJJMRZ35.SGD","IXUS","JULI","BNO","EUDG","IMFL","MOTI","QBIF","TILC","DRIP","EASG","TOUS","ARLI","RODM","USOI","WCMG","IXC","PDEV","IBUF","EFZ","WWJD","RFDI","HAWX","IMAR","UIVM","DIG","USE","BK4550","FHIL","WCMI","TLCI","HFXI","ERX","IQSI","CVIE","DBE","SPXT","BK4578","DBC","VEU","DINT","VDE","DWMF","APIE","NBIE","OEFA","UGA","LU0070302665.USD","IJUN","BK4020","IDMO","BAIV","VEFA","TIIV","WEEI","SEIE","IVSI","DRLL","LU0320765489.SGD","DXIV","CEFA","IQDF","SPDW","TXUE","DBEU","IAUG","GSIE","IDEV","IMAY","MEDX","IJUL","RINT","WTIU","OAIM","PEJ","BUFI","OVF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665317041","title":"Gilead Sciences (GILD) Receives a Buy from Bernstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2665317041","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665317041?lang=en_us&edition=fundamental","pubTime":"2026-09-08 00:25","pubTimestamp":1788798346,"startTime":"0","endTime":"0","summary":"Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences today and set a price target of $160.00. Breen covers the Healthcare se...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/gilead-sciences-gild-receives-a-buy-from-bernstein-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/gilead-sciences-gild-receives-a-buy-from-bernstein-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1839511570.USD","LU2112291526.USD","IBB","LU1674673428.USD","LU1571399168.USD","BIB","LABU","LU1778281490.HKD","LU0234570918.USD","MEDI","IE00B7SZLL34.SGD","GILD","LU2089984988.USD","LU1585245621.USD","XLV","LU1934455863.HKD","LU1934455194.USD","LU2324357040.USD","LU0823416689.USD","SG9999015978.USD","LU2468319806.SGD","BK4566","BK4585","SG9999015945.SGD","LU0289739699.SGD","SG9999015952.SGD","BK4139","LU0965508806.USD","TMED","BK4578","BK4550","IE00BZ1G4Q59.USD","BMED","LU0882574055.USD","IE00BSNM7G36.USD","BBH","IE00BKVL7J92.USD","XBI","IE00B3T34201.USD","BK4588","LU1066051498.USD","IE00B19Z3B42.SGD","TBXU","LU0122379950.USD","IE0002270589.USD","LU0114720955.EUR","BK4581","IBBQ","LU1037948541.HKD","LU1934455277.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665317208","title":"Novartis AG Falls Monday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2665317208","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665317208?lang=en_us&edition=fundamental","pubTime":"2026-09-08 00:15","pubTimestamp":1788797700,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novartis AG  dropped 3.2% to CHF125.46 Monday on what proved to be an overall unfavorable trading session for the stock market, with the Swiss Market Index SMI Index  falling 0.8% to 14,279.38.Novartis AG closed CHF7.22 short of its 52-week high of CHF132.68, which the company achieved on September 3, 2026.Trading volume was 3,077,526, compared to the 50-day average trading volume of 2,290,037.Data source: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00BFTCPJ56.SGD","NVS","BK4588","BK4532","MEDX","BK4007","BK4578","BK4585","LU0211331839.USD","IE00BJT1NW94.SGD","IE0002141913.USD","LU0208291251.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","PPH","LU0320765489.SGD","LU0070302665.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665176793","title":"Citi says Novartis news increases likelihood Crispr prioritizes next-gen CTX321","url":"https://stock-news.laohu8.com/highlight/detail?id=2665176793","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665176793?lang=en_us&edition=fundamental","pubTime":"2026-09-07 23:20","pubTimestamp":1788794419,"startTime":"0","endTime":"0","summary":"After Novartis (NVS) reported that pelacarsen’s Phase 3 HORIZON study failed to demonstrate a statistically significant reduction in major adverse ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citi-says-novartis-news-increases-likelihood-crispr-prioritizes-next-gen-ctx321-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citi-says-novartis-news-increases-likelihood-crispr-prioritizes-next-gen-ctx321-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU0211331839.USD","BK4588","IE0002141913.USD","BK4578","PPH","NVS","BK4532","LU0320765489.SGD","IE00BJJMRZ35.SGD","LU0208291251.USD","IE0009355771.USD","MEDX","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0070302665.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665552317","title":"Citi sees limited immediate downside for Ionis after pelacarsen failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2665552317","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665552317?lang=en_us&edition=fundamental","pubTime":"2026-09-07 23:15","pubTimestamp":1788794109,"startTime":"0","endTime":"0","summary":"After Ionis’ (IONS) partner Novartis (NVS) disclosed that the pelacarsen Phase 3 Lp(a)HORIZON study failed to meet its primary endpoint of cardiova...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citi-sees-limited-immediate-downside-for-ionis-after-pelacarsen-failure-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citi-sees-limited-immediate-downside-for-ionis-after-pelacarsen-failure-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0211331839.USD","BK4588","NVS","BK4007","PPH","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU0070302665.USD","IONS","MEDX","IE00B2B36J28.USD","LU0208291251.USD","IE00B4R5TH58.HKD","IE0009355771.USD","BK4139","IE0002141913.USD","BK4585","BK4532","BK4578","LU0320765489.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665311682","title":"BofA sees low single-digit percentage downside for Novartis on pelacarsen miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2665311682","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665311682?lang=en_us&edition=fundamental","pubTime":"2026-09-07 20:00","pubTimestamp":1788782433,"startTime":"0","endTime":"0","summary":"After Novartis (NVS) announced pelacarsen missed its primary endpoint of reducing cardiovascular events in the Phase 3 HORIZON study, BofA sees low...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bofa-sees-low-single-digit-percentage-downside-for-novartis-on-pelacarsen-miss-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bofa-sees-low-single-digit-percentage-downside-for-novartis-on-pelacarsen-miss-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002141913.USD","BK4578","IE00BJT1NW94.SGD","LU0208291251.USD","BK4007","LU0070302665.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","BK4532","PPH","MEDX","BK4585","LU0211331839.USD","BK4588","IE00B2B36J28.USD","LU0320765489.SGD","IE0009355771.USD","NVS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665572390","title":"Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665572390","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665572390?lang=en_us&edition=fundamental","pubTime":"2026-09-07 16:03","pubTimestamp":1788768180,"startTime":"0","endTime":"0","summary":"Novartis shares fell after the Swiss drugmaker said an experimental medicine failed to reduce cardiovascular risk in a late-stage clinical trial.Shares in Novartis were down 3.2% in European morning t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0320765489.SGD","PPH","IE00BJT1NW94.SGD","LU0070302665.USD","MEDX","BK4007","BK4588","BK4578","LU0211331839.USD","BK4532","NVS","LU0208291251.USD","BK4585","IE0002141913.USD","IE00B4R5TH58.HKD","IE0009355771.USD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665397422","title":"Novartis India to Acquire 'Minipress' Trademarks from Pfizer","url":"https://stock-news.laohu8.com/highlight/detail?id=2665397422","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665397422?lang=en_us&edition=fundamental","pubTime":"2026-09-07 15:43","pubTimestamp":1788767020,"startTime":"0","endTime":"0","summary":"BRIEF-Novartis India To Acquire 'Minipress' Trademarks From PfizerSept 7 (Reuters)-Novartis India LtdNOIN.BO:TO ACQUIRE 'MINIPRESS' TRADEMARKS FROM PFIZERSource text:ID:nBSE74jJ9yFurther company coverage:NOIN.BO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260907:nFWN44Y00E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234572021.USD","LU0456855351.SGD","LU0058720904.USD","MEDX","BK4007","BK4550","LU0070302665.USD","IE00BBT3K403.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU2596442595.SGD","BK4578","IE00B19Z3581.USD","LU0225284248.USD","SGXZ57979304.SGD","BK4568","BK4533","BK4532","SG9999001176.SGD","LU0122379950.USD","LU0306806265.USD","SG9999003800.SGD","IE00BLSP4452.SGD","NVS","LU0211331839.USD","SG9999002224.SGD","BK4588","LU1057294990.SGD","IE0009355771.USD","IE00B4R5TH58.HKD","LU1894683348.USD","LU0225771236.USD","IE00B19Z3B42.SGD","BK4599","LU1066051498.USD","BK4592","LU0321505439.SGD","LU1883839398.USD","LU0985481810.HKD","SG9999013999.USD","LU0306807586.USD","BK4581","IE00B2B36J28.USD","BK4585","IE00BFTCPJ56.SGD","LU0320765489.SGD","IE000M9KFDE8.USD","LU0289739699.SGD","LU0321505868.SGD","IE00BLSP4239.USD","LU0868494617.USD","LU0170899867.USD","LU1894683264.USD","IE0002270589.USD","IE00B3T34201.USD","OZEM","PFE","LU1023059063.AUD","PPH","BK4534","SG9999001176.USD","SG9999002232.USD","SG9999011175.SGD","IE00BJT1NW94.SGD","LU0208291251.USD","LU1066053197.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104786890","title":"Second Clinical Trial Blow in a Week for Novartis as Heart Drug Disappoints, Dragging Down Amgen Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1104786890","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104786890?lang=en_us&edition=fundamental","pubTime":"2026-09-07 15:22","pubTimestamp":1788765738,"startTime":"0","endTime":"0","summary":"Swiss pharma giant Novartis AG (NVS.US) has suffered another clinical trial setback, marking the second high-profile candidate to fail in late-stage studies within a single week. The latest casualty...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2112291526.USD","IE00BJT1NW94.SGD","PJP","BK4534","BK4588","LU1571399168.USD","LU2468319806.SGD","IE00BJJMRZ35.SGD","BK4585","BK4581","LU1983299246.USD","BBH","LU0208291251.USD","IE00B4R5TH58.HKD","BK4578","IE00BFTCPJ56.SGD","LU2242652126.USD","BIB","LU2242646821.SGD","TBXU","BK4532","IBB","NVS","LU2089984988.USD","LU0058720904.USD","LU0320765992.SGD","LU0289739699.SGD","LU0122379950.USD","LU1023059063.AUD","LU1057294990.SGD","SG9999001440.SGD","IE00B2B36J28.USD","BK4139","LU0109394709.USD","BK4007","IE0002141913.USD","AMGN","LU0211331839.USD","LU0889565916.HKD","IE0009355771.USD","PPH","LU0868494617.USD","LU0320765489.SGD","IBBQ","BK4566","LU0070302665.USD","LU1061106388.HKD","PBE","MEDX","BK4599","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665392965","title":"Novartis Heart-Trial Failure Could be Mitigated by Investor Caution","url":"https://stock-news.laohu8.com/highlight/detail?id=2665392965","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665392965?lang=en_us&edition=fundamental","pubTime":"2026-09-07 15:04","pubTimestamp":1788764640,"startTime":"0","endTime":"0","summary":"0703 GMT - An experimental Novartis medicine missed the target in a late-stage clinical trial, but the hit to the Swiss drugmaker's share price could be mitigated by investors' skepticism about the study, analysts at Citi say in a research note. The drug, pelacarsen, reduced the levels of a fatty particle in the blood known as Lp, but this didn't translate to clinical outcomes, Citi says. \"We think market expectations of a positive trial were already cautious, with question marks around the magnitude of benefit and difficulty in commercialization even if the study had met the endpoint, which we think could limit the impact of the trial failure on the share price,\" the analysts say.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","PPH","NVS","IE00B4R5TH58.HKD","LU0320765489.SGD","IE00BFTCPJ56.SGD","BK4588","LU0070302665.USD","BK4585","LU0208291251.USD","IE00B2B36J28.USD","BK4578","BK4007","IE00BJJMRZ35.SGD","MEDX","LU0211331839.USD","IE0002141913.USD","BK4532","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665391143","title":"Novartis India - Deal Valued at 12.50 Bln Rupees","url":"https://stock-news.laohu8.com/highlight/detail?id=2665391143","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665391143?lang=en_us&edition=fundamental","pubTime":"2026-09-07 13:56","pubTimestamp":1788760577,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260907:nFWN44Y00E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","IE00B2B36J28.USD","LU0320765489.SGD","BK4588","NVS","MEDX","LU0211331839.USD","BK4532","BK4578","PPH","IE00BJJMRZ35.SGD","LU0208291251.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0070302665.USD","BK4007","IE0002141913.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665684391","title":"Novartis Shares to Take Hit from Cholesterol Trial Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2665684391","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665684391?lang=en_us&edition=fundamental","pubTime":"2026-09-07 13:43","pubTimestamp":1788759780,"startTime":"0","endTime":"0","summary":"0543 GMT - Novartis shares are likely to take a hit from news that a cholesterol drug candidate failed to reduce the risk of severe cardiovascular events like heart attacks and strokes in a late-stage trial, J.P. Morgan analysts say in a research note. Consensus estimates for Novartis included $1 billion in 2030 sales from the drug, called pelacarsen, the analysts say. Shares in the Swiss drugmaker are likely to be off 2% to 3% on Monday as a result, they add. Upcoming trial results for del-desiran, an experimental treatment for genetic neuromuscular disorder myotonic dystrophy type 1, are likely to be positive and could allow Novartis to more than erase stock weakness caused by the pelacarsen results, according to JPM.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Novartis Shares to Take Hit from Cholesterol Trial Failure","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","BK4588","IE00BJJMRZ35.SGD","BK4585","LU0208291251.USD","IE00B4R5TH58.HKD","BK4578","IE00BFTCPJ56.SGD","BK4532","NVS","IE00B2B36J28.USD","BK4007","IE0002141913.USD","LU0211331839.USD","PPH","IE0009355771.USD","LU0320765489.SGD","LU0070302665.USD","MEDX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":104,"code":"91000000","status":"200"}]}}